Streamlining Nonclinical Development with FDA NAMs
FDA’s draft guidance on the validation of New Approach Methodologies (NAMs) is reshaping how nonclinical programs are designed and justified. This webinar explores how sponsors can apply NAMs to streamline development, improve human relevance, and support IND decision-making within a weight-of-evidence framework. We will break down FDA expectations for validation, including context of use and..
